KR20140090996A - R(+)-n-폼일-프로파길-아미노인단 - Google Patents

R(+)-n-폼일-프로파길-아미노인단 Download PDF

Info

Publication number
KR20140090996A
KR20140090996A KR1020147012454A KR20147012454A KR20140090996A KR 20140090996 A KR20140090996 A KR 20140090996A KR 1020147012454 A KR1020147012454 A KR 1020147012454A KR 20147012454 A KR20147012454 A KR 20147012454A KR 20140090996 A KR20140090996 A KR 20140090996A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
rasagiline
formyl
propargyl
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147012454A
Other languages
English (en)
Korean (ko)
Inventor
무함마드 사파디
앤톤 프렌켈
미갈 케이사르
대니트 리히트
엘리에제르 바하르
라미 리도르-하다스
마리나 졸코브스키
라헬 코헨
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20140090996A publication Critical patent/KR20140090996A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/03—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020147012454A 2011-10-10 2012-10-09 R(+)-n-폼일-프로파길-아미노인단 Withdrawn KR20140090996A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545422P 2011-10-10 2011-10-10
US61/545,422 2011-10-10
PCT/US2012/059356 WO2013055687A2 (en) 2011-10-10 2012-10-09 R(+)-n-formyl-propargyl-aminoindan

Publications (1)

Publication Number Publication Date
KR20140090996A true KR20140090996A (ko) 2014-07-18

Family

ID=48042235

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147012454A Withdrawn KR20140090996A (ko) 2011-10-10 2012-10-09 R(+)-n-폼일-프로파길-아미노인단

Country Status (15)

Country Link
US (1) US9346746B2 (cg-RX-API-DMAC7.html)
EP (1) EP2766002A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014534196A (cg-RX-API-DMAC7.html)
KR (1) KR20140090996A (cg-RX-API-DMAC7.html)
CN (1) CN103874487A (cg-RX-API-DMAC7.html)
AR (1) AR088297A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012323349A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014008555A2 (cg-RX-API-DMAC7.html)
CA (1) CA2851276A1 (cg-RX-API-DMAC7.html)
EA (1) EA201490761A1 (cg-RX-API-DMAC7.html)
HK (1) HK1200315A1 (cg-RX-API-DMAC7.html)
IL (1) IL231721A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014004308A (cg-RX-API-DMAC7.html)
WO (1) WO2013055687A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403043B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007217349B9 (en) * 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
KR20100107028A (ko) * 2008-01-11 2010-10-04 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 제형, 그들의 제법 및 용도
EP2285214B1 (en) * 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
WO2011042812A1 (en) * 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ATE346598T1 (de) * 1994-01-10 2006-12-15 Teva Pharma 1-aminoindanderivate und zusammensetzungen hiervon
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DK0966435T3 (da) 1996-12-18 2005-08-15 Teva Pharma Aminoindanderivater
AU775885B2 (en) * 1999-10-27 2004-08-19 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
EP1567152B1 (en) 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
US7619077B2 (en) 2003-02-06 2009-11-17 University Of Georgia Research Foundation Nucleic acids encoding a galacturonosyl tranferase enzyme (GALAT1) from arabidopsis
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
AU2007217349B9 (en) 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EA016843B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Таннат разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
KR20100107028A (ko) 2008-01-11 2010-10-04 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 제형, 그들의 제법 및 용도
EP2285214B1 (en) 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
US7968749B2 (en) 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
AU2009260733B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
WO2011042812A1 (en) 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
BR112013010308A2 (pt) 2010-10-26 2016-07-05 Teva Pharma rasagilina de deutério enriquecido
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
US20130089611A1 (en) 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Also Published As

Publication number Publication date
WO2013055687A2 (en) 2013-04-18
ZA201403043B (en) 2015-08-26
BR112014008555A2 (pt) 2017-04-18
EP2766002A4 (en) 2015-07-01
HK1200315A1 (en) 2015-08-07
IL231721A0 (en) 2014-05-28
AU2012323349A1 (en) 2014-05-22
AR088297A1 (es) 2014-05-21
MX2014004308A (es) 2014-07-24
US20130089612A1 (en) 2013-04-11
EA201490761A1 (ru) 2014-11-28
NZ624206A (en) 2016-11-25
CA2851276A1 (en) 2013-04-18
US9346746B2 (en) 2016-05-24
WO2013055687A3 (en) 2013-07-25
CN103874487A (zh) 2014-06-18
JP2014534196A (ja) 2014-12-18
EP2766002A2 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
KR20140090996A (ko) R(+)-n-폼일-프로파길-아미노인단
KR20140084153A (ko) R(+)-n-메틸-프로파길-아미노인단
KR20140074388A (ko) 라사길린 시트라마이드
US7619117B1 (en) Rasagiline formulations and processes for their preparation
CN102985090B (zh) 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途
US20110152381A1 (en) 3-keto-n-propargyl-1-aminoindan
AU2009275665A1 (en) Polymorphic form of rasagiline mesylate
CN104395291B (zh) N‑乙基‑4‑羟基‑1‑甲基‑5‑(甲基(2,3,4,5,6‑五羟基己基)氨基)‑2‑氧代‑n‑苯基‑1,2‑二氢喹啉‑3‑甲酰胺
JP2023010754A (ja) デューテトラベナジンの類似体、その調製及び使用
NZ624206B2 (en) R(+)-n-formyl-propargyl-aminoindan

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000